261 related articles for article (PubMed ID: 29704232)
1. Prognostic and microRNA profile analysis for CD44 positive expression pediatric posterior fossa ependymoma.
Shu C; Wang Q; Yan X; Wang J
Clin Transl Oncol; 2018 Nov; 20(11):1439-1447. PubMed ID: 29704232
[TBL] [Abstract][Full Text] [Related]
2. Altered MicroRNA Expression Is Associated with Tumor Grade, Molecular Background and Outcome in Childhood Infratentorial Ependymoma.
Zakrzewska M; Fendler W; Zakrzewski K; Sikorska B; Grajkowska W; Dembowska-Bagińska B; Filipek I; Stefańczyk Ł; Liberski PP
PLoS One; 2016; 11(7):e0158464. PubMed ID: 27390862
[TBL] [Abstract][Full Text] [Related]
3. Chromosome 1q gain and tenascin-C expression are candidate markers to define different risk groups in pediatric posterior fossa ependymoma.
Araki A; Chocholous M; Gojo J; Dorfer C; Czech T; Heinzl H; Dieckmann K; Ambros IM; Ambros PF; Slavc I; Haberler C
Acta Neuropathol Commun; 2016 Aug; 4(1):88. PubMed ID: 27550150
[TBL] [Abstract][Full Text] [Related]
4. A coordinated approach for the assessment of molecular subgroups in pediatric ependymomas using low-cost methods.
de Sousa GR; Lira RCP; de Almeida Magalhães T; da Silva KR; Nagano LFP; Saggioro FP; Baroni M; Marie SKN; Oba-Shinjo SM; Brandelise S; de Paula Queiroz RG; Brassesco MS; Scrideli CA; Tone LG; Valera ET
J Mol Med (Berl); 2021 Aug; 99(8):1101-1113. PubMed ID: 33903940
[TBL] [Abstract][Full Text] [Related]
5. Utility of copy number variants in the classification of intracranial ependymoma.
Evenson M; Cai C; Hucthagowder V; McNulty S; Neidich J; Kulkarni S; Dahiya S
Cancer Genet; 2020 Jan; 240():66-72. PubMed ID: 31794935
[TBL] [Abstract][Full Text] [Related]
6. Prognostic relevance of miR-124-3p and its target TP53INP1 in pediatric ependymoma.
Margolin-Miller Y; Yanichkin N; Shichrur K; Toledano H; Ohali A; Tzaridis T; Michowitz S; Fichman-Horn S; Feinmesser M; Pfister SM; Witt H; Tabori U; Bouffet E; Ramaswamy V; Hawkins C; Taylor MD; Yaniv I; Avigad S
Genes Chromosomes Cancer; 2017 Aug; 56(8):639-650. PubMed ID: 28437838
[TBL] [Abstract][Full Text] [Related]
7. Heterogeneity within the PF-EPN-B ependymoma subgroup.
Cavalli FMG; Hübner JM; Sharma T; Luu B; Sill M; Zapotocky M; Mack SC; Witt H; Lin T; Shih DJH; Ho B; Santi M; Emery L; Hukin J; Dunham C; McLendon RE; Lipp ES; Gururangan S; Grossbach A; French P; Kros JM; van Veelen MC; Rao AAN; Giannini C; Leary S; Jung S; Faria CC; Mora J; Schüller U; Alonso MM; Chan JA; Klekner A; Chambless LB; Hwang EI; Massimino M; Eberhart CG; Karajannis MA; Lu B; Liau LM; Zollo M; Ferrucci V; Carlotti C; Tirapelli DPC; Tabori U; Bouffet E; Ryzhova M; Ellison DW; Merchant TE; Gilbert MR; Armstrong TS; Korshunov A; Pfister SM; Taylor MD; Aldape K; Pajtler KW; Kool M; Ramaswamy V
Acta Neuropathol; 2018 Aug; 136(2):227-237. PubMed ID: 30019219
[TBL] [Abstract][Full Text] [Related]
8. Review of ependymomas: assessment of consensus in pathological diagnosis and correlations with genetic profiles and outcome.
Sasaki A; Hirato J; Hirose T; Fukuoka K; Kanemura Y; Hashimoto N; Kodama Y; Ichimura K; Sakamoto H; Nishikawa R
Brain Tumor Pathol; 2019 Apr; 36(2):92-101. PubMed ID: 30929114
[TBL] [Abstract][Full Text] [Related]
9. Association of MicroRNAs with the Clinicopathologic Characteristics of Ependymoma.
Ahram M; Amarin JZ; Suradi HH; Abdelhamid SS; Makhamreh MM; Bawadi RM; Al-Hussaini M
J Mol Neurosci; 2018 Nov; 66(3):307-313. PubMed ID: 30255441
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical analysis of H3K27me3 demonstrates global reduction in group-A childhood posterior fossa ependymoma and is a powerful predictor of outcome.
Panwalkar P; Clark J; Ramaswamy V; Hawes D; Yang F; Dunham C; Yip S; Hukin J; Sun Y; Schipper MJ; Chavez L; Margol A; Pekmezci M; Chung C; Banda A; Bayliss JM; Curry SJ; Santi M; Rodriguez FJ; Snuderl M; Karajannis MA; Saratsis AM; Horbinski CM; Carret AS; Wilson B; Johnston D; Lafay-Cousin L; Zelcer S; Eisenstat D; Silva M; Scheinemann K; Jabado N; McNeely PD; Kool M; Pfister SM; Taylor MD; Hawkins C; Korshunov A; Judkins AR; Venneti S
Acta Neuropathol; 2017 Nov; 134(5):705-714. PubMed ID: 28733933
[TBL] [Abstract][Full Text] [Related]
11. Telomerase activation in posterior fossa group A ependymomas is associated with dismal prognosis and chromosome 1q gain.
Gojo J; Lötsch D; Spiegl-Kreinecker S; Pajtler KW; Neumayer K; Korbel P; Araki A; Brandstetter A; Mohr T; Hovestadt V; Chavez L; Kirchhofer D; Ricken G; Stefanits H; Korshunov A; Pfister SM; Dieckmann K; Azizi AA; Czech T; Filipits M; Kool M; Peyrl A; Slavc I; Berger W; Haberler C
Neuro Oncol; 2017 Sep; 19(9):1183-1194. PubMed ID: 28371821
[TBL] [Abstract][Full Text] [Related]
12. Molecular sub-group-specific immunophenotypic changes are associated with outcome in recurrent posterior fossa ependymoma.
Hoffman LM; Donson AM; Nakachi I; Griesinger AM; Birks DK; Amani V; Hemenway MS; Liu AK; Wang M; Hankinson TC; Handler MH; Foreman NK
Acta Neuropathol; 2014 May; 127(5):731-45. PubMed ID: 24240813
[TBL] [Abstract][Full Text] [Related]
13. Radiology Profile as a Potential Instrument to Differentiate Between Posterior Fossa Ependymoma (PF-EPN) Group A and B.
Yonezawa U; Karlowee V; Amatya VJ; Takayasu T; Takano M; Takeshima Y; Sugiyama K; Kurisu K; Yamasaki F
World Neurosurg; 2020 Aug; 140():e320-e327. PubMed ID: 32428725
[TBL] [Abstract][Full Text] [Related]
14. Newly Diagnosed Metastatic Intracranial Ependymoma in Children: Frequency, Molecular Characteristics, Treatment, and Outcome in the Prospective HIT Series.
Benesch M; Mynarek M; Witt H; Warmuth-Metz M; Pietsch T; Bison B; Pfister SM; Pajtler KW; Kool M; Schüller U; Pietschmann K; Juhnke BO; Tippelt S; Fleischhack G; Schmid I; Kramm CM; Vorwerk P; Beilken A; Classen CF; Hernáiz Driever P; Kropshofer G; Imschweiler T; Lemmer A; Kortmann RD; Rutkowski S; von Hoff K
Oncologist; 2019 Sep; 24(9):e921-e929. PubMed ID: 30850560
[TBL] [Abstract][Full Text] [Related]
15. Differential expression profiles of microRNAs as potential biomarkers for the early diagnosis of lung cancer.
Zhang Y; Sui J; Shen X; Li C; Yao W; Hong W; Peng H; Pu Y; Yin L; Liang G
Oncol Rep; 2017 Jun; 37(6):3543-3553. PubMed ID: 28498428
[TBL] [Abstract][Full Text] [Related]
16. TET2 promotor methylation and TET2 protein expression in pediatric posterior fossa ependymoma.
Pierscianek D; Teuber-Hanselmann S; Ahmadipour Y; Darkwah Oppong M; Unteroberdörster M; Müller O; Jabbarli R; Sure U; Zhu Y; El Hindy N
Neuropathology; 2020 Apr; 40(2):138-143. PubMed ID: 31777116
[TBL] [Abstract][Full Text] [Related]
17. Expression and Clinical Significance of Translation Regulatory Long Non-Coding RNA 1 (TRERNA1) in Ependymomas.
Malgulwar PB; Nambirajan A; Singh M; Suri V; Sarkar C; Sharma MC
Pathol Oncol Res; 2020 Jul; 26(3):1975-1981. PubMed ID: 31489574
[TBL] [Abstract][Full Text] [Related]
18. Identification of biomarkers and construction of a microRNA-mRNA regulatory network for ependymoma using integrated bioinformatics analysis.
Yang B; Dai JX; Pan YB; Ma YB; Chu SH
Oncol Lett; 2019 Dec; 18(6):6079-6089. PubMed ID: 31788082
[TBL] [Abstract][Full Text] [Related]
19. Peritoneal fluid modifies the microRNA expression profile in endometrial and endometriotic cells from women with endometriosis.
Braza-Boïls A; Salloum-Asfar S; Marí-Alexandre J; Arroyo AB; González-Conejero R; Barceló-Molina M; García-Oms J; Vicente V; Estellés A; Gilabert-Estellés J; Martínez C
Hum Reprod; 2015 Oct; 30(10):2292-302. PubMed ID: 26307093
[TBL] [Abstract][Full Text] [Related]
20. Identification of microRNAs as potential prognostic markers in ependymoma.
Costa FF; Bischof JM; Vanin EF; Lulla RR; Wang M; Sredni ST; Rajaram V; Bonaldo Mde F; Wang D; Goldman S; Tomita T; Soares MB
PLoS One; 2011; 6(10):e25114. PubMed ID: 22053178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
